We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+28.34%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$15.2B
AUM Growth
+$1.87B
Cap. Flow
+$90.5M
Cap. Flow %
0.6%
Top 10 Hldgs %
84.66%
Holding
125
New
12
Increased
14
Reduced
21
Closed
27

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$50.5M
2
AMRN
Amarin Corp
AMRN
+$43.1M
3
INSM icon
Insmed
INSM
+$26M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$19M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$10.8M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$22.4M
2
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$20.8M
3
HALO icon
Halozyme
HALO
+$14.6M
4
EXEL icon
Exelixis
EXEL
+$11M
5
XNCR icon
Xencor
XNCR
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 91.42%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRNB
26
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$52.2M 0.34%
+1,787,807
New +$50.5M
TCDA
27
DELISTED
Tricida, Inc. Common Stock
TCDA
$48.9M 0.32%
1,600,000
– –
ECYT
28
DELISTED
Endocyte, Inc. Common Stock
ECYT
$45.3M 0.3%
2,548,069
+270,270
+12% +$4.64M
ACGN
29
DELISTED
Aceragen Inc
ACGN
$43.1M 0.28%
284,631
+120
+0% +$17.1K
INSM icon
30
Insmed
INSM
$22.6B
$37.4M 0.25%
1,851,982
+1,151,982
+165% +$26M
NGNE icon
31
Neurogene
NGNE
$648M
$32M 0.21%
546,708
– –
ABEO icon
32
Abeona Therapeutics
ABEO
$342M
$28M 0.18%
87,375
– –
SLDB icon
33
Solid Biosciences
SLDB
$791M
$27.7M 0.18%
39,192
– –
LKFT
34
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$26.7M 0.18%
237,191
-22,703
-9% -$2.4M
XNCR icon
35
Xencor
XNCR
$1.45B
$23.5M 0.15%
602,495
-269,577
-31% -$11M
MYOK
36
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$23.3M 0.15%
357,215
-75,906
-18% -$4.46M
MRUS
37
DELISTED
Merus
MRUS
$22.9M 0.15%
1,160,014
– –
QURE icon
38
uniQure
QURE
$2.76B
$22M 0.15%
605,000
– –
SGMO
39
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$21.8M 0.14%
1,283,923
– –
CMTA
40
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$21.6M 0.14%
1,933,624
+741,029
+62% +$7.8M
ZYME icon
41
Zymeworks
ZYME
$1.61B
$20.6M 0.14%
1,311,085
– –
AIMT
42
DELISTED
Aimmune Therapeutics
AIMT
$18.4M 0.12%
673,908
– –
BLCM
43
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$16.5M 0.11%
267,782
-141,563
-35% -$9.58M
BOLD
44
DELISTED
Audentes Therapeutics, Inc
BOLD
$15.6M 0.1%
393,222
– –
CFRX
45
DELISTED
ContraFect Corporation
CFRX
$14.8M 0.1%
8,941
– –
SYRE icon
46
Spyre Therapeutics
SYRE
$8.26B
$13.3M 0.09%
55,515
– –
ANAB icon
47
AnaptysBio
ANAB
$1.53B
$11.3M 0.07%
113,086
+40,000
+55% +$3.32M
CPRX
48
DELISTED
Catalyst Pharmaceutical
CPRX
$11M 0.07%
2,900,000
-721,962
-20% -$2.26M
PHXM
49
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$9.31M 0.06%
108,597
-200,000
-65% -$20.8M
NVAX icon
50
Novavax
NVAX
$1.21B
$8.87M 0.06%
+235,916
New +$6.64M
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2018 Portfolio in Review

As of Q3 2018, Baker Bros. Advisors held 125 positions worth $15.2B, up 14% from $13.3B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q3 2018 filing shows 12 new, 14 increased, 21 reduced and 27 closed positions. Its largest new stake was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M. The largest sale was bluebird bio, an estimated $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M.
  • Baker Bros. Advisors added most to Amarin Corp in Q3 2018, an estimated $43.1M increase.
  • Baker Bros. Advisors's biggest Q3 2018 reduction was bluebird bio, cutting an estimated $22.4M.
  • Baker Bros. Advisors fully exited Exelixis in Q3 2018, selling an estimated $11M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $15.2B portfolio in Q3 2018.
  • Baker Bros. Advisors opened 12 new positions and closed 27 in Q3 2018.
  • Baker Bros. Advisors's portfolio value rose 14% quarter-over-quarter to $15.2B.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.